J. Schneidewind , S. von Sengbusch , D. Schmidt , K. Lange
{"title":"Human factor in the use of automated insulin delivery systems: Real-world effects in children with type 1 diabetes after 2 years of use (AID-A study)","authors":"J. Schneidewind , S. von Sengbusch , D. Schmidt , K. Lange","doi":"10.1016/j.diabres.2025.112477","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>This study aimed to assess the metabolic effects, changes in daily life, and diabetes burden associated with automated insulin delivery (AID) systems in children in a real-world setting after 2 years of use.</div></div><div><h3>Methods</h3><div>Longitudinal glycaemic data (glycated haemoglobin [HbA1c], time in range [TiR], time below range [TbR], glucose management indicator [GMI]), body mass index (BMI), and AID system usage were collected from 111 children with type 1 diabetes at 12 and 24 months of AID use. After 1 year, adolescents and parents completed questionnaires on diabetes-related distress (P-PAID-C, P-PAID-T, and PAID-T) and experienced changes.</div></div><div><h3>Results</h3><div>Regardless of age or previous therapy, the HbA1c level decreased from 8.1 % (65 mmol/mol) to 7.7 % (61 mmol/mol), TiR increased from 55 % to 64 %, TbR decreased from 2.6 % to 1.8 %, and GMI (7.6 % vs. 7.3 %) improved after 1 year. After 2 years, HbA1c (7.6 % [60 mmol/mol]), TiR (62 %), TbR (1.3 %), and GMI (7.4 %) levels stabilised. Adolescents and parents reported improvements in daily life (i.e. sleep, stress, fear of hypoglycaemia). However, the BMI-SDS scores increased in the first year.</div></div><div><h3>Conclusions</h3><div>AID system use is associated with clinically relevant improvements in glycaemic control and decrease in daily diabetes-related burden on affected children and their parents.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112477"},"PeriodicalIF":7.4000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168822725004917","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Aims
This study aimed to assess the metabolic effects, changes in daily life, and diabetes burden associated with automated insulin delivery (AID) systems in children in a real-world setting after 2 years of use.
Methods
Longitudinal glycaemic data (glycated haemoglobin [HbA1c], time in range [TiR], time below range [TbR], glucose management indicator [GMI]), body mass index (BMI), and AID system usage were collected from 111 children with type 1 diabetes at 12 and 24 months of AID use. After 1 year, adolescents and parents completed questionnaires on diabetes-related distress (P-PAID-C, P-PAID-T, and PAID-T) and experienced changes.
Results
Regardless of age or previous therapy, the HbA1c level decreased from 8.1 % (65 mmol/mol) to 7.7 % (61 mmol/mol), TiR increased from 55 % to 64 %, TbR decreased from 2.6 % to 1.8 %, and GMI (7.6 % vs. 7.3 %) improved after 1 year. After 2 years, HbA1c (7.6 % [60 mmol/mol]), TiR (62 %), TbR (1.3 %), and GMI (7.4 %) levels stabilised. Adolescents and parents reported improvements in daily life (i.e. sleep, stress, fear of hypoglycaemia). However, the BMI-SDS scores increased in the first year.
Conclusions
AID system use is associated with clinically relevant improvements in glycaemic control and decrease in daily diabetes-related burden on affected children and their parents.
期刊介绍:
Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.